Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Trevena Inc (TRVN)
NASDAQ:TRVN
Holding TRVN?
Track your performance easily
TRVN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.35 - $25.75
Previous Close$4.01
Volume43.78K
Average Volume (3M)35.63K
Market Cap
$3.42M
Enterprise Value$18.58M
Total Cash (Recent Filing)$16.37M
Total Debt (Recent Filing)$31.53M
Price to Earnings (P/E)―
Beta0.71
Next Earnings
Nov 05, 2024EPS Estimate
-$7.75Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-55.32
Shares Outstanding852,933
10 Day Avg. Volume112,771
30 Day Avg. Volume35,635
Standard Deviation0.27
R-Squared0.04
Alpha-0.06
Financial Highlights & Ratios
Price to Book (P/B)-0.18
Price to Sales (P/S)2.46
Price to Cash Flow (P/CF)-0.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue4.76
Enterprise Value/Gross Profit-11.13
Enterprise Value/Ebitda-0.73
Forecast
1Y Price Target
$75.00Price Target Upside1770.32% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Trevena News
PremiumCompany Announcements
Trevena Faces Leadership Changes Amidst Financial Challenges
PremiumCompany Announcements
Trevena Executives Terminated but Remain as Advisors
Bulls Say, Bears Say
Bulls Say
CollaborationTrevena is collaborating with NIH to evaluate TRV045 as a potential disease-modifying agent for the prevention of seizures.
Financial HealthThe company ended 1Q24 with ~$24MM in cash and equivalents, which is expected to be sufficient to fund operations into 2025.
Product PotentialTRV045 demonstrates blockbuster potential for the treatment of diabetic neuropathy pain and epilepsy.
Bears Say
Commercial SupportTrevena previously announced that it would reduce Olinvyk's commercial support to preserve capital.
Sales PerformanceOlinvyk sales remained disappointing in 4Q at -$84K likely due to product returns.
Workforce ReductionThe company also announced reducing yearly expenses by $3.5-$4.0M and reducing ~35% of its workforce.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
TRVN FAQ
What was Trevena Inc’s price range in the past 12 months?
Trevena Inc lowest stock price was $3.35 and its highest was $25.75 in the past 12 months.
What is Trevena Inc’s market cap?
Currently, no data Available
When is Trevena Inc’s upcoming earnings report date?
Trevena Inc’s upcoming earnings report date is Nov 05, 2024 which is 7 days ago.
How were Trevena Inc’s earnings last quarter?
Trevena Inc released its earnings results on Aug 08, 2024. The company reported -$5.75 earnings per share for the quarter, beating the consensus estimate of -$10.125 by $4.375.
Is Trevena Inc overvalued?
According to Wall Street analysts Trevena Inc’s price is currently Undervalued.
Does Trevena Inc pay dividends?
Trevena Inc does not currently pay dividends.
What is Trevena Inc’s EPS estimate?
Trevena Inc’s EPS estimate is -$7.75.
How many shares outstanding does Trevena Inc have?
Trevena Inc has 852,933 shares outstanding.
What happened to Trevena Inc’s price movement after its last earnings report?
Trevena Inc reported an EPS of -$5.75 in its last earnings report, beating expectations of -$10.125. Following the earnings report the stock price went up 8.902%.
Which hedge fund is a major shareholder of Trevena Inc?
Among the largest hedge funds holding Trevena Inc’s share is Harbourvest Partners Llc. It holds Trevena Inc’s shares valued at N/A.
---
Trevena Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$75.00 (1770.32% Upside)
$75.00 (1770.32% Upside)
Blogger Sentiment
Bearish
TRVN Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 101.0 Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.5%
Last 30 Days ▲ 24.2%
Last 30 Days ▲ 24.2%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-76.75%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-40.96%
Trailing 12-Months
Company Description
Trevena Inc
Trevena, Inc. is a biopharmaceutical company, which focuses on the development and commercialization of innovative treatment options that target and treat diseases affecting the central nervous system, or CNS. The company product pipeline consists of Olinvo, TRV250, and TRV734. Trevena was founded by Robert Joseph Lefkowitz, Scott DeWire, Howard A. Rockman, Jonathan Violin and Erin Whalen on November 9, 2007 and is headquartered in Chesterbrook, PA.
---
TRVN Earnings Call
Q3 2023
0:00 / 0:00
---
TRVN Stock 12 Month Forecast
Average Price Target
$75.00
▲(1770.32% Upside)
Technical Analysis
Best Analysts Covering TRVN
1 Year
1 Year Success Rate
0/21 ratings generated profit
1 Year Average Return
-75.21%
reiterated a buy rating 3 months ago
Copying Jason Butler's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -75.21% per trade.
---